New strategy for chemical modification of hyaluronic acid: Preparation of functionalized derivatives and their use in the formation of novel biocompatible hydrogels

Journal of Biomedical Materials Research

Volumn 47, Issue 2, 1999, Pages 152-169

  Bulpitt, Paul ^a   Aeschlimann, Daniel ^a  

^a University of Wisconsin Health   (United States)

Author keywords

Bone formation; Crosslinking; Cytokine delivery; Hyaluronic acid; Tissue repair

Indexed keywords

BIOCOMPATIBILITY; BIOMATERIALS; BONE; CHEMICAL MODIFICATION; COMPOSITION EFFECTS; CONTROLLED DRUG DELIVERY; CROSSLINKING; DERIVATIVES; ORGANIC ACIDS;

BONE FORMATION; CYTOKINE DELIVERY; HYALURONIC ACID;

HYDROGELS;

BONE MORPHOGENETIC PROTEIN 2; CYTOKINE; GLUCURONIC ACID; HYALURONIC ACID; POLYSACCHARIDE; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BIOCOMPATIBILITY; BIODEGRADATION; BONE MATRIX; CELL DIFFERENTIATION; CHEMICAL MODIFICATION; CHEMICAL REACTION; CROSS LINKING; HYDROGEL; OSSIFICATION; TISSUE REPAIR;

ANIMALS; BIOCOMPATIBLE MATERIALS; BONE MORPHOGENETIC PROTEINS; CELL DIFFERENTIATION; CHONDROCYTES; CROSS-LINKING REAGENTS; DRUG SYNERGISM; HYALURONIC ACID; RATS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0032819928     PISSN: 00219304     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4636(199911)47:2<152::AID-JBM5>3.0.CO;2-I     Document Type: Article

References (48)

1. Buckwalter JA, Mankin HJ. Articular cartilage: Degeneration and osteoarthrosis, repair, regeneration, and transplantation. J Bone Joint Surg 1997;79-A:612-632.
2. Brittberg M, Lindahl A, Nilsson A, Ohlsson C, Isaksson O, Peterson L. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N Engl J Med 1994;331:889-895.
3. Hunziker EB, Rosenberg LC. Repair of partial-thickness defects in articular cartilage: Cell recruitment from the synovial membrane. J Bone Joint Surg 1996;78-A:721-733.
4. Laurent TC, Fraser JRE. Hyaluronan. FASEB J. 1992;6:2397-2404.
5. Mörgelin M, Heinegard D, Engel J, Paulsson M. The cartilage proteoglycan aggregate: Assembly through combined protein-carbohydrate and protein interactions. Biophys Chem 1994;50: 113-128.
6. Knudson CB, Knudson W. Hyaluronan-binding proteins in development, tissue homeostasis, and disease. FASEB J 1993;7: 1233-1241.
7. Maleski MP, Knudson CB. Hyaluronan-mediated aggregation of limb bud mesenchyme and mesenchymal condensation during chondrogenesis. Exp Cell Res 1996;225:55-66.
8. Balazs EA, Laurent TC. Round table discussion : New applications for hyaluronan. In: Laurent TC, editor. The chemistry, biology and medical applications of hyaluronan and its derivatives. London: Portland Press; 1998. p 325-326.
9. Weiss C. Viscoseparation and viscoprotection as therapeutic modalities in the musculoskeletal system. In: Laurent TC, editor. The chemistry, biology and medical applications of hyaluronan and its derivatives. London: Portland Press; 1998. p 255-266.
10. Band PA. Hyaluronan derivatives: Chemistry and clinical applications. In: Laurent TC, editor. The chemistry, biology and medical applications of hyaluronan and its derivatives. London: Portland Press; 1998. p 33-42.
11. Larsen NE, Balazs EA. Drug delivery systems using hyaluronan and its derivatives. Adv Drug Delivery Rev 1991;7:279-293.
12. Drobnik J. Hyaluronan in drug delivery. Adv Drug Delivery Rev 1991;7:295-308.
13. Pouyani T, Prestwich GD. Functionalized derivative of hyaluronic acid oligosaccharides: Drug carriers and novel biomaterials. Bioconj Chem 1994;5:339-347.
14. della Valle F, Romeo A. Crosslinked esters of hyaluronic acid. US Patent No. 4,957,744; 1990.
15. della Valle F, Romeo A. Total or partial esters of hyaluronic acid. US Patent No. 5,336,767; 1994.
16. Hubbell JA, Pathak CP, Sawhney AS, Desai NP, Hill JL. Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers. US Patent No. 5,410,016; 1995.
17. Balazs EA, Leshchiner A. Crosslinked gels of hyaluronic acid and products containing such gels. US Patent No. 4,582,865; 1986.
18. Balazs EA, Leshchiner A, Leshchiner A, Band P. Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues. US Patent No. 4,713,448; 1987.
19. Curvall M, Lindberg B, Lonngren J. Carbohydr Res 1975;41: 235-239.
20. 125I-tyramine-cellobiose to amino groups after partial N-deacetylation. Anal Biochem 1988;175:397-407.
21. Danishefsky I, Siskovic E. Carbohydr Res 1971;16:199-201.
22. Ogamo A, Matzuzaki K, Uchiyama H, Nagasawa K. Carbohydr Res 1982;105:69-85.
23. Kuo J-W, Swann DA, Prestwich GD. Chemical modification of hyaluronic acid by carbodiimides. Bioconj Chem 1991;2:232-241.
24. Kurzer F, Douraghi-Zedeh K. Advances in the chemistry of carbodiimides. Chem Rev 1967;67:107-152.
25. Vercruysse KP, Marecak DM, Marecek JF, Prestwich GD. Synthesis and in vitro degradation of new polyvalent hydrazide crosslinked hydrogels of hyaluronic acid. Bioconj Chem 1997; 8:686-694.
26. Bitter T, Muir H. A modified uronic acid carbazole reaction. Anal Biochem 1962;4:330-334.
27. McPherson JM, Wallace DG, Sawamura SJ, Conti A, Condell RA, Wade S, Piez KA. Collagen fibrillogenesis in vitro: A characterization of fibril quality as a function of assembly conditions. Collagen Rel Res 1985;5:119-135.
28. Wong SS, editor. Chemistry of protein conjugation and crosslinking. Boca Raton, FL: CRC Press; 1993. p 27.
29. Cha JS. Recent developments in the synthesis of aldehydes by reduction of carboxylic acids and their derivatives with metal hydrides. Org Prep Proc Int 1989;21:451-477.
30. McKee CM, Penno MB, Cowman M, Burdick MD, Strieter RM, Bao C, Noble PW. Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. J Clin Invest 1996;98:2403-2413.
31. Hodge-Dufour J, Noble PW, Horton MR, Bao C, Wysoka M, Burdick MD, Strieter RM, Trichieri G, Puré E. Induction of IL-12 and chemokines by hyaluronan requires adhesion-dependent priming of resident but not elicited macrophages. J Immunol 1997;159:2492-2500.
32. Noble PW, McKee CM, Horton MR. Induction of inflammatory gene expression by low molecular weight hyaluronan fragments in macrophages. In: Laurent TC, editor. The chemistry, biology and medical applications of hyaluronan and its derivatives. London: Portland Press; 1998. p 219-225.
33. Papakonstantinou E, Misevic GN. Isolation and characterization of a new class of acidic glycans implicated in sea urchin embryonal cell adhesion. J Cell Biochem 1993;53:98-113.
34. Fraser JRE, Brown TJ, Laurent TC. Catabolism of hyaluronan. In: Laurent TC, editor. The chemistry, biology and medical applications of hyaluronan and its derivatives. London: Portland Press; 1998. p 85-92.
35. Laurencin C, Domb A, Morris C, Brown V, Chasin M, McConnell R, Lange N, Langer R. Poly(anhydride) administration in high doses in vivo: Studies of biocompatibility and toxicology. J Biomed Mater Res 1990;24:1463-1481.
36. Wang EA, Rosen V, DíAlessandro JS, Bauduy M, Cordes P, Harada T, Israel DI, Hewick RM, Kerns KM, LaPan P, Luxenberg DP, McQuaid D, Moutsatsos IK, Nove J, Wozney JM. Recombinant human bone morphogenetic protein induces bone formation. Proc Natl Acad Sci USA 1990;87:2220-2224.
37. Sampath TK, Maliakal JC, Hauschka PV, Jones WK, Sasak H, Tucker RF, White KH, Coughlin JE, Tucker MM, Pang RHL, Corbett C, Oezkaynak E, Oppermann H, Rueger DC. Recombinant human osteogenic protein-1 (hOP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro. J Biol Chem 1992;267:20352-20362.
38. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH, Fauci AS. Transforming growth factor type β: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986;83:4167-4171.
39. Yang EY, Moses HL. Transforming growth factor β1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol 1990;111:731-741.
40. Joyce ME, Roberts AB, Sporn MB, Bolander ME. Transforming growth factor-β and the initiation of chondrogenesis and osteogenesis in the rat femur. J Cell Biol 1990;110:2195-2207.
41. Bentz H, Thompson AY, Armstrong R, Chang RJ, Piez KA, Rosen DM. Transforming growth factor-β2 enhances the osteoinductive activity of a bovine bone-derived fraction containing bone morphogenetic protein-2 and 3. Matrix 1991;11:269-275.
42. Hill DJ, Logan A. Peptide growth factors and their interactions during chondrogenesis. Prog Growth Factor Res 1992;4:45-68.
43. Hunziker EB, Wagner J, Zapf J. Differential effects of insulin-like growth factor-1 and growth hormone on developmental stages of rat growth plate chondrocytes in vivo. J Clin Invest 1994;93:1078-1086.
44. Takano S, Gately S, Neville ME, Herblin WF, Gross JL, Engelhard H, Perricone M, Eidsvoog K, Brem S. Suramin, an anti-cancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res 1994;54:2654-2660.
45. Bentz H, Schroeder JA, Estridge TD. Improved local delivery of TGF-β2 by binding to injectable fibrillar collagen via difunctional polyethylene glycol. J Biomed Mater Res 1998;39:539-548.
46. Paralkar VM, Nandedkar AK, Pointer RH, Kleinmann HK, Reddi AH. Interaction of osteogenin, a heparin binding bone morphogenetic protein, with type IV collagen. J Biol Chem 1990;265:17281-17284.
47. Paralkar VM, Vukicevic S, Reddi AH. Transforming growth factor-β1 binds to collagen IV of basement membrane matrix: Implications for development. Dev Biol 1991;143:303-308.
48. Richards FM, Knowles JR. Glutaraldehyde as a protein crosslinking reagent. J Mol Biol 1968;37:231-233.